tetano
Editor, Senior Moderator
Cell Rep
. 2025 Apr 2;44(4):115499.
doi: 10.1016/j.celrep.2025.115499. Online ahead of print. A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
Sharon L Schendel[SUP] 1 [/SUP], Xiaoying Yu[SUP] 1 [/SUP], Peter J Halfmann[SUP] 2 [/SUP], Jarjapu Mahita[SUP] 1 [/SUP], Brendan Ha[SUP] 1 [/SUP], Kathryn M Hastie[SUP] 1 [/SUP], Haoyang Li[SUP] 1 [/SUP], Daniel Bedinger[SUP] 3 [/SUP], Camille Troup[SUP] 3 [/SUP], Kan Li[SUP] 4 [/SUP], Natalia Kuzmina[SUP] 5 [/SUP], Jordi B Torrelles[SUP] 6 [/SUP], Jennifer E Munt[SUP] 7 [/SUP], Melissa Maddocks[SUP] 7 [/SUP], Mary Osei-Twum[SUP] 8 [/SUP], Heather M Callaway[SUP] 1 [/SUP]; CoVIC-DB Team[SUP] 1 [/SUP]; Stephen Reece[SUP] 9 [/SUP], Anne Palser[SUP] 10 [/SUP], Paul Kellam[SUP] 11 [/SUP], S Moses Dennison[SUP] 4 [/SUP], Richard H C Huntwork[SUP] 4 [/SUP], Gillian Q Horn[SUP] 4 [/SUP], Milite Abraha[SUP] 4 [/SUP], Elizabeth Feeney[SUP] 4 [/SUP], Luis Martinez-Sobrido[SUP] 6 [/SUP], Paula A Pino[SUP] 12 [/SUP], Amberlee Hicks[SUP] 12 [/SUP], Chengjin Ye[SUP] 6 [/SUP], Jun-Gyu Park[SUP] 12 [/SUP], Billie Maingot[SUP] 12 [/SUP], Sivakumar Periasamy[SUP] 13 [/SUP], Michael Mallory[SUP] 7 [/SUP], Trevor Scobey[SUP] 7 [/SUP], Marie-Noelle Lepage[SUP] 8 [/SUP], Natalie St-Amant[SUP] 8 [/SUP], Sarwat Khan[SUP] 8 [/SUP], Anaïs Gambiez[SUP] 1 [/SUP]; Coronavirus Immunotherapeutic Consortium; Ralph S Baric[SUP] 14 [/SUP], Alexander Bukreyev[SUP] 15 [/SUP], Luc Gagnon[SUP] 8 [/SUP], Timothy Germann[SUP] 3 [/SUP], Yoshihiro Kawaoka[SUP] 16 [/SUP], Georgia D Tomaras[SUP] 4 [/SUP], Bjoern Peters[SUP] 17 [/SUP], Erica Ollmann Saphire[SUP] 18 [/SUP]
Affiliations
The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.
Keywords: COVID-19; CP: Immunology; SARS-CoV-2 spike protein; coronavirus; high-resolution epitope binning; neutralization; therapeutic antibodies.
. 2025 Apr 2;44(4):115499.
doi: 10.1016/j.celrep.2025.115499. Online ahead of print. A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
Sharon L Schendel[SUP] 1 [/SUP], Xiaoying Yu[SUP] 1 [/SUP], Peter J Halfmann[SUP] 2 [/SUP], Jarjapu Mahita[SUP] 1 [/SUP], Brendan Ha[SUP] 1 [/SUP], Kathryn M Hastie[SUP] 1 [/SUP], Haoyang Li[SUP] 1 [/SUP], Daniel Bedinger[SUP] 3 [/SUP], Camille Troup[SUP] 3 [/SUP], Kan Li[SUP] 4 [/SUP], Natalia Kuzmina[SUP] 5 [/SUP], Jordi B Torrelles[SUP] 6 [/SUP], Jennifer E Munt[SUP] 7 [/SUP], Melissa Maddocks[SUP] 7 [/SUP], Mary Osei-Twum[SUP] 8 [/SUP], Heather M Callaway[SUP] 1 [/SUP]; CoVIC-DB Team[SUP] 1 [/SUP]; Stephen Reece[SUP] 9 [/SUP], Anne Palser[SUP] 10 [/SUP], Paul Kellam[SUP] 11 [/SUP], S Moses Dennison[SUP] 4 [/SUP], Richard H C Huntwork[SUP] 4 [/SUP], Gillian Q Horn[SUP] 4 [/SUP], Milite Abraha[SUP] 4 [/SUP], Elizabeth Feeney[SUP] 4 [/SUP], Luis Martinez-Sobrido[SUP] 6 [/SUP], Paula A Pino[SUP] 12 [/SUP], Amberlee Hicks[SUP] 12 [/SUP], Chengjin Ye[SUP] 6 [/SUP], Jun-Gyu Park[SUP] 12 [/SUP], Billie Maingot[SUP] 12 [/SUP], Sivakumar Periasamy[SUP] 13 [/SUP], Michael Mallory[SUP] 7 [/SUP], Trevor Scobey[SUP] 7 [/SUP], Marie-Noelle Lepage[SUP] 8 [/SUP], Natalie St-Amant[SUP] 8 [/SUP], Sarwat Khan[SUP] 8 [/SUP], Anaïs Gambiez[SUP] 1 [/SUP]; Coronavirus Immunotherapeutic Consortium; Ralph S Baric[SUP] 14 [/SUP], Alexander Bukreyev[SUP] 15 [/SUP], Luc Gagnon[SUP] 8 [/SUP], Timothy Germann[SUP] 3 [/SUP], Yoshihiro Kawaoka[SUP] 16 [/SUP], Georgia D Tomaras[SUP] 4 [/SUP], Bjoern Peters[SUP] 17 [/SUP], Erica Ollmann Saphire[SUP] 18 [/SUP]
Affiliations
- PMID: 40184253
- DOI: 10.1016/j.celrep.2025.115499
The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.
Keywords: COVID-19; CP: Immunology; SARS-CoV-2 spike protein; coronavirus; high-resolution epitope binning; neutralization; therapeutic antibodies.